#EAU20 Virtual - Radioligand therapy in metastatic castration-resistant prostate cancer
EAU
Europe/Madrid GMT+2
Description
Radioligand therapy in metastatic castration-resistant prostate cancer
Thematic session 04
Fri 17 July
18:30 - 20:00
Location:Virtual room 2Chairs: A. Briganti, Milan (IT)
M. Heck, Munich (DE)
D. Murphy, Melbourne (AU)
Learning objectives
Prostate-specific membrane antigen (PSMA) offers great potential not only as a target for diagnostic but also for therapeutic purposes. The present session highlights the application of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Indication, limitations and future developments will be discussed.
18:30 - 18:45
Current and future radioligands (ligands and emitters)
M. Gauthé, Paris (FR)
18:45 - 19:00
Limitations of PSMA based on prostate cancer biology
P. Rescigno, London (GB)
19:00 - 19:15
Critical assessment of radioligand therapy
T. Steuber, Hamburg (DE)
19:15 - 19:50
Case-based debate (PSMA)-targeted radioligand therapy: For which patients, which stages?
19:15 - 19:20
Case presentation
I. Tsaur, Mainz (DE)
19:20 - 19:30
Treatment options: Medical oncologist
UV Vogl, Bellinzona (CH)
19:30 - 19:40
Treatment options: Nuclear medicine
M. Eiber, Munich (DE)
19:40 - 19:50
Radioligand therapy for less advanced cases: Urologist
A. Heidenreich, Cologne (DE)
19:50 - 20:00
Discussion, questions and answers
A. Briganti, Milan (IT)
M. Heck, Munich (DE)
D. Murphy, Melbourne (AU)
A. Briganti, M. Heck, D. Murphy
Current and future radioligands (ligands and emitters)
Inglês
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Speakers
M. Gauthé, P. Rescigno, T. Steuber, I. Tsaur, UV Vogl, M. Eiber, A. Heidenreich
Link to the Event
Banner to the Event
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.